Table 1.
Vaccination.
| Clinical Characteristics | Value |
|---|---|
| Total number of adolescents | 40 |
| Age, year (range; IQR) | 16 (13–18; 14.5–17) |
| Male sex, n (%) | 26 (65) |
| Asian, n (%) | 40 (100) |
| Dose of vaccine with symptoms, n (%) | |
| 1st dose, n (%) | 25 (62.5) |
| 2nd dose, n (%) | 15 (37.5) |
| Days from vaccination to symptom occurrence (range; IQR) | 2 (0–29; 1–5) |
| Cardiac symptoms, n (%) | |
| Chest pain, pressure, chest discomfort | 40 (100) |
| Dyspnea, shortness of breath | 7 (17.5) |
| Palpitations | 5 (12.5) |
| Syncope | 1 (2.5) |
| Treatment | |
| NSAIDS, n (%) | 31 (77.5) |
| IVIG, n (%) | 1 (2.5) |
| Glucocorticoids, n (%) | 8 (20.0) |
| Colchicine, n (%) | 2 (5.0) |
| Only supportive | 6 (15.0) |
| Hospital stay, days (range; IQR) | 1 (0–8; 0–3) |
| ICU admission, n (%) | 5 (12.5) |
| PICU stay, days (range; IQR) | 3 (1–6; 1–3.75) |
| Adolescents requiring inotropics/vasoactive agents, n (%) | 1 (2.5) |
| Adolescents requiring ECMO, n (%) | 0 |
| Mortality, n (%) | 0 |
COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; IVIG, intravenous immunoglobulin; IQR, interquartile range; NSAIDS, nonsteroidal anti-inflammatory drugs; PICU, pediatric intensive care unit.